# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

31. **Sohonos**: Approved on August 16, 2023, Sohonos, containing palovarotene, is used to reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva.

32. **Elfabrio**: Elfabrio, with the active ingredient pegunigalsidase alfa-iwxj, was approved on May 9, 2023, for the treatment of confirmed Fabry disease.

33. **Miebo**: Approved on May 18, 2023, Miebo, containing perfluorhexyloctane, is indicated for the treatment of signs and symptoms of dry eye disease.

34. **Jaypirca**: Jaypirca, with the active ingredient pirtobrutinib, was approved on January 27, 2023, for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor.

35. **Veopoz**: Approved on August 18, 2023, Veopoz, containing pozelimab-bbfg, is indicated for the treatment of patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.

36. **Vanflyta**: Vanflyta, with the active ingredient quizartinib, was approved on July 20, 2023, for use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria.

37. **Augtyro**: Approved on November 15, 2023, Augtyro, containing repotrectinib, is used for the treatment of ROS1-positive non-small cell lung cancer.

38. **Zynyz**: Zynyz, with the active ingredient retifanlimab-dlwr, was approved on March 22, 2023, for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma.
